Mersana Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Mersana Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 14 Jun 2021 | Lorem |
| Mersana’s XMT-1522 Her2+ breast cancer toxicity, efficacy results too early to validate platform but encouraging - experts | 19 Jun 2018 | Manasi Vaidya |
| Mersana’s Phase I ADC oncology study to enroll 120-140 patients in 2018, work with CRO Novella Clinical Research-CMO | 06 Oct 2017 | Manasi Vaidya |
| Mersana employs CRO Novella for Phase I ADC breast cancer therapy - CEO | 30 Nov 2016 | Alissa Fleck |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer